Ionis Pharmaceuticals Inc $ 52.78 1.51 (2.95%)
On watch
Volume:
885,079
Avg Vol (1m):
911,717
Market Cap $:
7.43 Bil
Enterprise Value $:
6.38 Bil
PE Ratio:
0.00
PB Ratio:
8.76
Current and historical daily P/E ratio for IONS (Ionis Pharmaceuticals Inc) from 1991 to Mar 07 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Ionis Pharmaceuticals stock (IONS) PE ratio as of Mar 07 2021 is 0.
More Details
Ionis Pharmaceuticals PE Ratio (TTM) Chart
EMBED
Ionis Pharmaceuticals PE Ratio (TTM) Historical Data
View and export this data going back to 1991. Start your Free Trial
Total 1245
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Ionis Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2021-03-07 | 0.0 | 2020-12-31 | 0.0 |
| 2021-03-05 | 0.0 | 2020-12-30 | 0.0 |
| 2021-03-04 | 0.0 | 2020-12-29 | 0.0 |
| 2021-03-03 | 0.0 | 2020-12-28 | 0.0 |
| 2021-03-02 | 0.0 | 2020-12-24 | 124.3 |
| 2021-03-01 | 0.0 | 2020-12-23 | 125.6 |
| 2021-02-26 | 0.0 | 2020-12-22 | 122.1 |
| 2021-02-25 | 0.0 | 2020-12-21 | 115.3 |
| 2021-02-24 | 0.0 | 2020-12-18 | 113.2 |
| 2021-02-23 | 0.0 | 2020-12-17 | 106.7 |
| 2021-02-22 | 0.0 | 2020-12-16 | 103.7 |
| 2021-02-19 | 0.0 | 2020-12-15 | 107.3 |
| 2021-02-18 | 0.0 | 2020-12-14 | 99.7 |
| 2021-02-17 | 0.0 | 2020-12-11 | 95.4 |
| 2021-02-16 | 0.0 | 2020-12-10 | 96.6 |
| 2021-02-15 | 0.0 | 2020-12-09 | 97.2 |
| 2021-02-12 | 0.0 | 2020-12-08 | 102.0 |
| 2021-02-11 | 0.0 | 2020-12-07 | 104.8 |
| 2021-02-10 | 0.0 | 2020-12-04 | 106.7 |
| 2021-02-09 | 0.0 | 2020-12-03 | 106.2 |
| 2021-02-08 | 0.0 | 2020-12-02 | 106.9 |
| 2021-02-05 | 0.0 | 2020-12-01 | 106.5 |
| 2021-02-04 | 0.0 | 2020-11-30 | 105.3 |
| 2021-02-03 | 0.0 | 2020-11-27 | 106.5 |
| 2021-02-02 | 0.0 | 2020-11-25 | 104.7 |
| 2021-02-01 | 0.0 | 2020-11-24 | 104.3 |
| 2021-01-29 | 0.0 | 2020-11-23 | 104.7 |
| 2021-01-28 | 0.0 | 2020-11-20 | 102.4 |
| 2021-01-27 | 0.0 | 2020-11-19 | 105.1 |
| 2021-01-26 | 0.0 | 2020-11-18 | 105.6 |
| 2021-01-25 | 0.0 | 2020-11-17 | 109.4 |
| 2021-01-22 | 0.0 | 2020-11-16 | 108.7 |
| 2021-01-21 | 0.0 | 2020-11-13 | 107.4 |
| 2021-01-20 | 0.0 | 2020-11-12 | 102.6 |
| 2021-01-19 | 0.0 | 2020-11-11 | 102.5 |
| 2021-01-15 | 0.0 | 2020-11-10 | 104.5 |
| 2021-01-14 | 0.0 | 2020-11-09 | 104.4 |
| 2021-01-13 | 0.0 | 2020-11-06 | 101.3 |
| 2021-01-12 | 0.0 | 2020-11-05 | 101.5 |
| 2021-01-11 | 0.0 | 2020-11-04 | 99.2 |
| 2021-01-08 | 0.0 | 2020-11-03 | 97.9 |
| 2021-01-07 | 0.0 | 2020-11-02 | 97.4 |
| 2021-01-06 | 0.0 | 2020-10-30 | 97.8 |
| 2021-01-05 | 0.0 | 2020-10-29 | 97.6 |
| 2021-01-04 | 0.0 | 2020-10-28 | 95.5 |
Ionis Pharmaceuticals PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Compare
NAS:EXEL
NAS:IMMU
NAS:ACAD
NAS:ASND
NAS:ALLO
NAS:JAZZ
NAS:RETA
NAS:XLRN
NAS:ADPT
NAS:IOVA
OCSE:NOVO B
ASX:CSL
NAS:VRTX
NAS:REGN
XKRX:207940
NAS:SGEN
NAS:MRNA
NAS:ALXN
XKRX:068270
NAS:INCY
Address
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).